Table 1.
Clinical trials using stem cells or progenitor cells against stroke.
| Authors | Year | Cell type | Key findings |
|---|---|---|---|
| Bang et al. | 2005 | MSCs | Cells were intravenously grafted twice within 9 weeks post-stroke. Better outcome in Barthel index after 1 year, but no effect on NIHSS and MRI scan. |
| Lee et al. | 2010 | MSCs | Intravenous cell grafting twice post-stroke with observation period of 5 years. Better outcome in mRS. |
| Bhasin et al. | 2011 | MSCs | Autologous intravenous MSC transplantation. Within 24 weeks, no significant side effects observed plus putative increased neural plasticity. |
| Bhasin et al. | 2013 | MSCs | Intravenous MSC transplantation followed by observation period of 24 weeks. Statistically improved modified Barthel Index and increased neural plasticity after stem cell treatment. No side effects. |
| Honmou et al. | 2011 | MSCs | Intravenous cell transplantation showed no side effects during 1 year of follow-up. Reduction of lesion volume by >20% after 1 week. |
| Savitz et al. | 2011 | MSCs | Intravenous transplantation of MSCs within 72 h post-stroke plus observation period of 6 months. No study-related side effects. Median NIHSS 13 before cell grafting and 3 after 6 months. |
| Savitz et al. | 2010 | MSCs | Intraarterial delivery of 99mTc-labeled MSCs. Significantly reduced intracerebral numbers of grafted cells after 24 h. No significant side effects for as long as 120 days. |
| Moniche et al. | 2012 | MSCs | Intraarterial infusion of MSCs between 5-9 days post-stroke. After 6 months, no side effects but also no improved functional outcome. |
| Suárez-Monteagudo et al. | 2009 | MSCs | Stereotactic transplantation of cells into 5 patients. Authors claim discrete functional improvement after 1 year. |
| Kondziolka et al. | 2000 | Cultured neuronal cells | Stereotactic delivery of cells with observation period of 18 months. Some functional improvement. No relevant safety issues. |
| Kondziolka et al. | 2005 | Cultured neuronal cells | Stereotactic cell delivery with maximal observation period of 24 months. Some functional improvement, but primary outcome was not met. No significant adverse events. |
| Savitz et al. | 2005 | Fetal lateral eminescence (=neural) cells | Cells were pre-treated with anti-MHC I antibody and intracerebrally delivered. Study was stopped after 5 patients. Significant side effects. |
| Rabinovich et al. | 2005 | Cell suspension from immature nervous and hemopoietic tissue | Intrathecal cell delivery in 10 patients. No significant side effects during 6 months of observation. |
The table describes the studies quoted in the main text with special regard to key findings, the cell type used and the year of publication. MRI: magnetic resonance imaging, mRS: modified Rankin Scale, MSCs: mesenchymal stem cells, NIHSS: National Institutes of Health Stroke Scale.